Results from the phase 2 Daro-PET study (NCT05900973) showed that prostate-specific membrane antigen (PSMA) expression was boosted with short-course darolutamide (Nubeqa) in patients with high-risk ...
The core foundation of precision medicine, and in turn, precision oncology, is a personalized approach to treatment that focuses on targeting specific molecular features that impact how cancer cells ...
Real world outcomes of darolutamide efficacy and safety in treating non-metastatic and metastatic hormone-sensitive prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting ...
Potential risk factors, course of disease, and clinical outcomes of neuroendocrine prostate cancer (NEPC): A retrospective analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting ...
A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery - the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results